Placebo + Valbenazine
Phase 3Active 1 views this week 0 watching⚡ Active
Interest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Dyskinesia
Conditions
Dyskinesia, Cerebral Palsy
Trial Timeline
Apr 15, 2022 → Jun 1, 2026
NCT ID
NCT05206513About Placebo + Valbenazine
Placebo + Valbenazine is a phase 3 stage product being developed by Neurocrine Biosciences for Dyskinesia. The current trial status is active. This product is registered under clinical trial identifier NCT05206513. Target conditions include Dyskinesia, Cerebral Palsy.
What happened to similar drugs?
3 of 8 similar drugs in Dyskinesia were approved
Approved (3) Terminated (1) Active (5)
Hype Score Breakdown
Clinical
17
Activity
12
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05206513 | Phase 3 | Active |
| NCT05110157 | Phase 3 | Completed |
Competing Products
20 competing products in Dyskinesia